HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
TBXA2R
thromboxane A2 receptor
Chromosome 19 Β· 19p13.3
NCBI Gene: 6915Ensembl: ENSG00000006638.14HGNC: HGNC:11608UniProt: P21731
162PubMed Papers
21Diseases
5Drugs
4Pathogenic Variants
FUNCTIONAL ROLE
Receptor
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein bindingnegative regulation of cell migration involved in sprouting angiogenesisplasma membranepositive regulation of blood pressurebleeding diathesis due to thromboxane synthesis deficiencyneurodegenerative diseaseAirway obstructionRecurrent thrombophlebitis
✦AI Summary

TBXA2R (thromboxane A2 receptor) is a G protein-coupled receptor that inhibits adenylyl cyclase and functions as a thromboxane A2 receptor involved in inflammatory responses and vascular regulation. The receptor positively regulates vasoconstriction, blood pressure, and cytosolic calcium signaling while negatively regulating cell migration during angiogenesis 1. TBXA2R operates through G protein-coupled receptor signaling pathways and can be activated not only by thromboxane A2 but also by F2-isoprostanes generated during oxidative stress 1. Functionally, TBXA2R serves as a scaffold protein through PDZ domain interactions with growth factor receptors, potentially modulating heterotrimeric G-protein signaling 2. Clinically, TBXA2R polymorphisms are associated with asthma susceptibility and phenotypes; specific risk alleles correlate with elevated IgE levels, eosinophilic inflammation, and reduced lung function, also predicting poor response to leukotriene receptor antagonist therapy 34. TBXA2R polymorphisms additionally associate with ischemic stroke risk 5. In cancer biology, elevated TBXA2R expression in breast tumors correlates with aggressive grade 3 disease and significantly shorter disease-free survival 6. In pulmonary fibrosis, TBXA2R upregulation in lung fibroblasts drives persistent myofibroblast activation through F2-isoprostane signaling, and TBXA2R antagonism protects against fibrosis development and promotes resolution 1. Germline mutations in TBXA2R cause platelet-type bleeding disorder 13.

Sources cited
1
TBXA2R polymorphism (+795T>C and +924T>C risk alleles) associated with higher IgE, eosinophil counts, lower FEV1, and poor response to montelukast in asthmatic children
PMID: 18031559
2
TBXA2R rs34377097 (R60L) polymorphism associated with pollen-induced asthma susceptibility and reduced FEV1/FVC ratio in Indian population
PMID: 36936944
3
TBXA2R polymorphisms (rs4523, rs768963, rs1131882) associated with increased ischemic stroke risk in meta-analysis
PMID: 32971583
4
TBXA2R expression elevated in breast tumors, particularly grade 3 tumors, and high TBXA2R expression correlates with shorter disease-free survival
PMID: 16250911
5
TBXA2R upregulated in lung fibroblasts during idiopathic pulmonary fibrosis; activated by F2-isoprostanes to drive myofibroblast activation; TBXA2R antagonism protects from and resolves lung fibrosis
PMID: 35728047
6
TBXA2R linked to GIPC3 gene in chromosome 19p13.3; GIPCs serve as scaffold proteins for TBXA2R and other receptors in G-protein signaling
PMID: 12011974
7
TBXA2R polymorphisms (rs8113232, rs3786989) associated with asthma-related symptoms including rhinitis but not asthma susceptibility
PMID: 22017802
Disease Associationsβ“˜21
bleeding diathesis due to thromboxane synthesis deficiencyOpen Targets
0.64Moderate
neurodegenerative diseaseOpen Targets
0.51Moderate
Airway obstructionOpen Targets
0.37Weak
Recurrent thrombophlebitisOpen Targets
0.37Weak
Abnormal platelet aggregationOpen Targets
0.30Weak
thrombotic diseaseOpen Targets
0.26Weak
allergic asthmaOpen Targets
0.26Weak
asthmaOpen Targets
0.22Weak
neuroinflammatory disorderOpen Targets
0.20Weak
genetic disorderOpen Targets
0.19Weak
COVID-19Open Targets
0.19Weak
blood platelet diseaseOpen Targets
0.18Weak
qualitative platelet defectOpen Targets
0.18Weak
Rhinitis, Allergic, PerennialOpen Targets
0.18Weak
Impaired thromboxane A2 agonist-induced platelet aggregationOpen Targets
0.15Weak
pulmonary arterial hypertensionOpen Targets
0.09Suggestive
Glanzmann thrombasthenia 1Open Targets
0.08Suggestive
triple-negative breast cancerOpen Targets
0.08Suggestive
Von Willebrand diseaseOpen Targets
0.08Suggestive
thrombocytopenia 7Open Targets
0.07Suggestive
Bleeding disorder, platelet-type, 13UniProt
Pathogenic Variants4
NM_001060.6(TBXA2R):c.416C>A (p.Ser139Ter)Likely pathogenic
Bleeding disorder, platelet-type, 13, susceptibility to
β˜…β˜†β˜†β˜†2023β†’ Residue 139
NM_001060.6(TBXA2R):c.787-2A>GLikely pathogenic
Abnormal platelet aggregation
β˜…β˜†β˜†β˜†2019
NM_001060.6(TBXA2R):c.82C>T (p.Pro28Ser)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2017β†’ Residue 28
NM_001060.6(TBXA2R):c.548G>A (p.Cys183Tyr)Likely pathogenic
Bleeding disorder, platelet-type, 13, susceptibility to
β˜†β˜†β˜†β˜†β†’ Residue 183
View on ClinVar β†—
Drug Targets5
PICOTAMIDEApproved
Thromboxane A2 receptor inhibitor
Recurrent thrombophlebitis
RAMATROBANPhase II/III
Thromboxane A2 receptor antagonist
Rhinitis, Allergic, Perennial
SERATRODASTApproved
Thromboxane A2 receptor antagonist
Airway obstruction
TERBOGRELPhase II
Thromboxane A2 receptor antagonist
pulmonary arterial hypertension
TERUTROBANPhase III
Thromboxane A2 receptor antagonist
thrombotic disease
Related Genes
GNB1Protein interaction99%GNA13Protein interaction99%AAMPProtein interaction89%CYSLTR2Protein interaction89%ADRA1DProtein interaction86%ADRA1BProtein interaction86%
Tissue Expression6 tissues
Liver
100%
Lung
77%
Heart
44%
Ovary
25%
Brain
13%
Bone Marrow
5%
Gene Interaction Network
Click a node to explore
TBXA2RGNB1GNA13AAMPCYSLTR2ADRA1DADRA1B
PROTEIN STRUCTURE
Preparing viewer…
PDB8XJN Β· 3.06 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.48LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.96 [0.64–1.48]
RankingsWhere TBXA2R stands among ~20K protein-coding genes
  • #2,779of 20,598
    Most Researched162 Β· top quartile
  • #571of 1,025
    FDA-Approved Drug Targets2
  • #3,710of 5,498
    Most Pathogenic Variants4
  • #15,051of 17,882
    Most Constrained (LOEUF)1.48
Genes detectedTBXA2R
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
TBXA2R gene polymorphism and responsiveness to leukotriene receptor antagonist in children with asthma.
PMID: 18031559
Clin Exp Allergy Β· 2008
1.00
2
Regulatory SNPs and transcriptional factor binding sites in ADRBK1, AKT3, ATF3, DIO2, TBXA2R and VEGFA.
PMID: 25483406
Transcription Β· 2014
0.90
3
Association of ORMDL3, STAT6 and TBXA2R gene polymorphisms with asthma.
PMID: 22017802
Int J Immunogenet Β· 2012
0.80
4
In silico analysis of single nucleotide polymorphism (rs34377097) of TBXA2R gene and pollen induced bronchial asthma susceptibility in West Bengal population, India.
PMID: 36936944
Front Immunol Β· 2023
0.70
5
Impact of pharmacogenetics on aspirin resistance: a systematic review.
PMID: 36918009
Arq Neuropsiquiatr Β· 2023
0.60